Transcenta Unveils Updated Efficacy Data from Osemitamab (TST001) Plus CAPOX as First-Line Treatment for G/GEJ Cancer Study at ESMO 2023 : vimarsana.com

Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all

Related Keywords

China , Shanghai , Hangzhou , Zhejiang , Suzhou , Jiangsu , Princeton , Massachusetts , United States , Beijing , Guangzhou , Guangdong , Madrid , Spain , Boston , Caroline Germa , Los Angeles , Transcenta Holding , Transcenta Immune Tolerance Breaking Technology , Transcenta Holding Limited , Clinical Development Centers In Princeton , Translational Research Center , Product Development Center , Global Medicine Development , Group Headquarters , Executive Vice President , Chief Medical , Manageable Safety , Immune Tolerance Breaking Technology , Orphan Drug Designation , Manufacturing Facility , Clinical Development Centers , External Partnering Center , Suzhou Industrial ,